NCT07185893View on ClinicalTrials.gov

A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors

NANot yet recruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

December 31, 2028

Conditions

Solid Tumor Malignancies, CancerCTIT-Chemotherapy Induced ThrombocytopeniaThrombocytopenia

Interventions

DRUG

Human Interleukin-11

Human Interleukin-11 for Injection (rhlL-11) 25 - 50 μg/kg, subcutaneous injection, once a day, for at least 7 - 10 days.

DRUG

Romiplostim N01

Administer Romiplostim N01 subcutaneously in the abdominal area. The initial dose is 3 μg/kg, once a week. The subsequent dose will be adjusted according to the patient's platelet count

Trial Locations (1)

Unknown

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors

lead

Jun wang

OTHER